



June 1, 2022

Anhui Zhong Lian Latex Gloves Manufacturing Co., Ltd.
% Boyle Wang
General Manager
Shanghai Truthful Information Technology Co., Ltd.
Room608, No.738, Shangcheng Rd., Pudong
Shanghai, Shanghai 200120
China

Re: K220488

Trade/Device Name: Disposable Nitrile Powder-Free Examination Gloves (Tested for Use with
Chemotherapy Drugs)

Regulation Number: 21 CFR 880.6250

Regulation Name: Non-Powdered Patient Examination Glove

Regulatory Class: Class I, reserved

Product Code: LZA, LZC

Dated: April 25, 2022

Received: May 2, 2022

Dear Boyle Wang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Bifeng Qian, M.D., Ph.D.
Acting Assistant Director
DHT4B: Division of Infection Control
and Plastic Surgery Devices
OHT4: Office of Surgical
and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)
K220488

Device Name

Disposable Nitrile Powder-Free Examination Gloves (Tested for Use with Chemotherapy Drugs)

Indications for Use (Describe)

A patient examination gloves is a disposable device intended for medical purpose that is worn on the examiner's hand or fingers to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978-05 Standard Practice for Assessment of Medical gloves to Permeation by Chemotherapy Drugs.

Chemotherapy Drug	Concentration	Breakthrough Detection Time in Minutes
Carmustine (BCNU)	3.3 mg/ml (3,300 ppm)	23.6 (23.6, 27.5, 25.2) Minutes
Cisplatin	1.0 mg/ml(1,000 ppm)	> 240 Minutes
Cyclophosphamide (Cytosan)	20.0 mg/ml(20,000 ppm)	> 240 Minutes
Dacarbazine	10 mg/ml (10,000 ppm)	> 240 Minutes
Doxorubicin HCl	2.0 mg/ml(2,000 ppm)	> 240 Minutes
Etoposide	20.0 mg/ml(20,000 ppm)	> 240 Minutes
Fluorouracil	50.0 mg/ml(50,000 ppm)	>240 Minutes
Methotrexate	25 mg/ml (25,000 ppm)	>240 Minutes
Mitomycin C	0.5 mg/ml (500 ppm)	>240 Minutes
Paclitaxel	6.0 mg/ml(6,000 ppm)	>240 Minutes
Thio Tepa	10.0 mg/ml(10,000 ppm)	37.4 (38.8, 37.4, 37.5) Minutes
Vincristine Sulfate	1 mg/ml (1,000 ppm)	> 240 Minutes

Please note that the following drugs have low permeation times: Carmustine (BCNU) 3.3 mg/ml 23.6 Minutes (min.); Thio Tepa 10.0 mg/ml 37.4 Minutes (min.). Warning: Please do not use with Carmustine (BCNU) and Thiotepa.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

K220488

This summary of 510(k) K220488 is being submitted in accordance with 21 CFR 807.92.

1.0 Submitter's Information

Name: ANHUI ZHONG LIAN LATEX GLOVES MANUFACTURING CO., LTD.

Address: GUZHEN ECONOMIC DEVELOPMENT ZONE BENGBU CITY
ANHUI CHINA

Contact: GUZHEN ECONOMIC DEVELOPMENT ZONE BENGBU CITY
ANHUI CHINA

Date of Preparation: 2022.05.26

Designated Submission Correspondent

Mr. Boyle Wang

Shanghai Truthful Information Technology Co., Ltd.

Room 1801, No. 161 Lujiazui East Rd., Pudong Shanghai, 200120 China

Tel: +86-21-50313932

Email: Info@truthful.com.cn

2.0 Device Information

Trade name: Disposable Nitrile Powder-Free Examination Gloves (Tested
for Use with Chemotherapy Drugs)

Common name: Patient Examination Gloves

Classification name: Non-powdered patient examination glove

Model(s): S, M, L, XL

3.0 Classification

Production code: LZA,LZC

Regulation number: 21CFR880.6250

Classification: Class I

Panel: General Hospital

4.0 Predicate Device Information

Manufacturer: Ever Growth (Vietnam) Co., Ltd.

Device: Disposable Powder Free Nitrile Examination Glove, Tested For

Use With Chemotherapy Drugs, Disposable Powder Free
Nitrile Examination Glove, Tested For Use With Chemotherapy
Drugs, Orange Color

510(k) number: K190860

5.0 Device Description

The subject device is single use, disposable gloves intended for medical purposes to be worn on the examiner's hands to prevent contamination between patient and examiner. The gloves are powder-free, ambidextrous with beaded cuff, blue colored, nitrile, and tested for use with chemotherapy drugs. The gloves are offered in four sizes: small, medium, large, and extra-large.

6.0 Indication for Use

A patient examination gloves is a disposable device intended for medical purpose that is worn on the examiner's hand or fingers to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978-05 *Standard Practice for Assessment of Medical gloves to Permeation by Chemotherapy Drugs*

Chemotherapy Drug	Concentration	Breakthrough Detection Time in Minutes (minutes)
Carmustine (BCNU)	3.3 mg/ml (3,300 ppm)	23.6 (23.6, 27.5, 25.2)
Cisplatin	1.0 mg/ml(1,000 ppm)	> 240
Cyclophosphamide (Cytosan)	20.0 mg/ml(20,000 ppm)	> 240
Dacarbazine	10 mg/ml (10,000 ppm)	> 240
Doxorubicin HCl	2.0 mg/ml(2,000 ppm)	> 240
Etoposide	20.0 mg/ml(20,000 ppm)	> 240
Fluorouracil	50.0 mg/ml(50,000 ppm)	> 240
Methotrexate	25 mg/ml (25,000 ppm)	> 240
Mitomycin C	0.5 mg/ml (500 ppm)	> 240
Paclitaxel	6.0 mg/ml(6,000 ppm)	> 240
Thio Tapa	10.0 mg/ml(10,000 ppm)	37.4 (38.8, 37.4, 37.5)
Vincristine Sulfate	1 mg/ml (1,000 ppm)	> 240

Please note that the following drugs have low permeation times:

Carmustine (BCNU) 3.3 mg/ml 23.6 Minutes (min.);

Thio Tapa 10.0 mg/ml 37.4 Minutes (min.).

Warning: Please do not use with Carmustine (BCNU) and Thiotepa.

7.0 Technological Characteristic Comparison Table

Table1-General Comparison

Item	Subject Device K220488	Predicate Device (K190860)	Remark
Product Code	LZA,LZC	LZA,LZC	Same
Regulation No.	21CFR880.6250	21CFR880.6250	Same
Class	I	I	Same
Intended Use/Indications for Use	A patient examination gloves is a disposable device intended for medical purpose that is worn on the examiner's hand or fingers to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978-05 Standard Practice for Assessment of Medical gloves to Permeation by Chemotherapy Drugs.	A patient examination gloves is a disposable device intended for medical purpose that is worn on the examiner's hand or fingers to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978-05 Standard Practice for Assessment of Medical gloves to Permeation by Chemotherapy Drugs.	Same
Powdered or Powered free	Powdered free	Powdered free	Same
Design Feature	Ambidextrous	Ambidextrous	Same
Sterility	Non-Sterile	Non-Sterile	Same
Labeling Information	Single-use indication, powder free, device color, device name, glove size and quantity,Non-Sterile, a statement of standard ASTM D6978-05 compliance and a summary of the testing results.	Single-use indication, powder free, device color, device name, glove size and quantity, Non-Sterile, a statement of standard ASTM D6978-05 compliance and a summary of the testing results.	Similar

Table2 Device Dimensions Comparison

Predicate Device(K190860)	Designation	Size					Tolerance
		XS	S	M	L	XL	

	Length, mm	230	230	230	230	230	min
	Width, mm	70	80	95	110	120	±10
	Thickness, mm:						
	Finger	0.05					min
	Palm	0.05					min
	Subject Device	Designation	Size				Tolerance
S			M	L	XL		
Length, mm		220	230	230	230	min	
Width, mm		80	95	110	120	±10	
Thickness, mm:							
Finger		0.05					min
Palm		0.05					min
Remark		Different					

Analysis: The physical dimensions are different with that of the predicate, but they all meet the requirements of ASTM D6319-19, so the differences do not raise any new safety or performance questions.

Table3 Performance Comparison

Item		Subject device K220488	Predicate device (K190860)	Remark	
Colorant		Blue	White, Orange	Different 1	
Physical Properties	Before Aging	Tensile Strength	14MPa, min	14MPa, min	Same
		Ultimate Elongation	500% min	500% min	Same
	After Aging	Tensile Strength	14MPa, min	14MPa, min	Same
		Ultimate Elongation	400%min	400%min	Same
	Comply with ASTM D6319		Comply with ASTM D6319		Same
Freedom from Holes	Be free from holes when tested in accordance with ASTM D5151 AQL=2.5	Be free from holes when tested in accordance with ASTM D5151 AQL=2.5		Same	
Powder Content	0.09-0.11 mg per glove, Meet the requirements of ASTM D6124	Meet the requirements of ASTM D6124		Same	
Chemotherapy Drugs Tested with Minimum Breakthrough	Carmustine (BCNU) 3.3 mg/ml: 23.6 Minutes (min.)	Carmustine (BCNU) 3.3 mg/ml: White:11.8 Minutes; Orange:31.6Minutes		Similar	
	Cisplatin 1.0 mg/ml: > 240	Cisplatin 1.0 mg/ml: >		Same	

Detection Time as Tested per ASTM D 6978	Minutes	240 Minutes	
	Cyclophosphamide (Cytoxan) 20.0 mg/ml: > 240 Minutes	Cyclophosphamide (Cytoxan) 20.0 mg/ml: > 240 Minutes	Same
	Dacarbazine 10 mg/ml:> 240 Minutes	Dacarbazine (DTIC) 10.0 mg/ml: >240 Minutes	Same
	Doxorubicin HCl 2.0 mg/ml: > 240 Minutes	Doxorubicin Hydrochloride 2.0 mg/ml: >240 Minutes	Similar
	Etoposide 20.0 mg/ml: > 240 Minutes	Etoposide (Toposar) 20.0 mg/ml: >240 Minutes	Similar
	Fluorouracil 50.0 mg/ml: > 240 Minutes	Fluorouracil 50.0 mg/ml: >240 Minutes	Same
	Methotrexate, 25 mg/ml (25,000 ppm): >240 Minutes	/	Different 2
	Mitomycin C, 0.5 mg/ml (500 ppm): >240 Minutes	/	
	Paclitaxel 6.0 mg/ml: >240 Minutes	Paclitaxel (Taxol) 6.0 mg/ml: >240 Minutes	Same
	Thio Tapa 10.0 mg/ml: 37.4 Minutes (min.)	Thio-Tapa 10.0 mg/ml: White:16.9 Minutes; Orange: 72.5 Minutes	Similar
Vincristine Sulfate, 1mg/ml (1,000 ppm): >240 Minutes	/	Different 2	

Analysis:

Different 1: The color of the subject device is different of that of the predicate. Biocompatibility testing was successfully completed for the subject device, demonstrating that any color differences do not affect the safety of the proposed device.

Different 2: The chemotherapy drug is different with that of the predicate, but they all meet the requirements of ASTM D6978-05(2019),so the differences do not raise any new safety or performance questions.

Table4 Safety Comparison

Item	Proposed device	Predicated device	Remark
Material	Nitrile	Nitrile	SAME
Biocompatibility	Irritation	Under the conditions of the study, not an irritant	Comply with ISO10993-10
	Sensitization	Under conditions of the study, not a sensitizer.	
	Cytotoxicity	Under the conditions of the study, the device is potentially cytotoxic	Comply with ISO10993-5
	Systemic toxicity	Under the conditions of the study, the device does not elicit a systemic toxicity response in the model animal.	Complies with ISO 10993-11 Third edition 2017-09
Label and Labeling	Meet FDA's Requirement	Meet FDA's Requirement	SAME

Analysis3: The proposed device is potentially cytotoxic, but all proposed devices are conducted the systemic toxicity test, the test results show that the proposed device is safe.

8.0 Summary of Non-Clinical Testing

Biocompatibility Testing

The biocompatibility evaluation for Disposable Nitrile Powder-Free Examination Gloves (Tested for Use with Chemotherapy Drugs) was conducted in accordance with the following standards:

ISO 10993-10:2010 *Biological Evaluation of Medical Devices - Part 10: Tests for Irritation And Skin Sensitization.*

ISO 10993-5:2009 *Biological Evaluation of Medical Devices - Part 5: Tests For In Vitro Cytotoxicity*

ISO 10993-11 Third edition 2017-09 *Biological evaluation of medical devices - Part 11: Tests for systemic toxicity*

Performance Testing (Bench)

Physical performance qualities of the proposed device were evaluated per ASTM D6319-10, *Standard Specification for Disposable Nitrile Powder-Free Examination Gloves for Medical Application.*

Permeation testing was conducted to support the addition of the labeling claim: *Tested for use with chemotherapy drugs.* In addition, the proposed device was tested according to ASTM D6978-05 (Reapproved 2019), *Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs*, in which minimum breakthrough times were determined for a wide range of chemotherapy drugs.

In summary, the performance testing of the subject device was conducted to adequately demonstrate the effectiveness of the device in accordance with the relevant test methods cited below:

- ASTM D6124-06 (Reapproved 2017), *Standard Test Method for Residual Powder on Medical Gloves*
- ASTM D5151-19, *Standard Test Method for Detection of Holes in Medical Gloves.*
- ASTM D6319-19, *Standard Specification for Disposable Nitrile Powder-Free Examination Gloves for Medical Application.*
- ASTM D 6978-05 (Reapproved 2019) ,*Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs.*
-

No.	Name of the Test Methodology / Standard	Purpose	Acceptance Criteria	Results
1	ISO 10993-10:2010 Biological Evaluation Of Medical Devices - Part 10: Tests For Irritation And Skin Sensitization.	This part of ISO 10993 assesses possible contact hazards from chemicals released from medical devices, which may produce skin and mucosal irritation, eye irritation or skin sensitization.	Skin Sensitization Test: provided grades less than 1, otherwise sensitization.	All grades are 0. All animals were survived and no abnormal signs were observed during the study.
2			Skin Irritation Test: If the primary irritation index is 0-0,4, the response category is Negligible. 0,5-1,9 means slight 2-4,9 means moderate 5-8 means severe	The primary irritation index is 0. The response of the proposed device was categorized as negligible under the test condition
3	ISO 10993-5:2009 Biological Evaluation Of Medical Devices - Part 5: Tests For In Vitro Cytotoxicity	This part of ISO 10993 describes test methods to assess the in vitro cytotoxicity of medical devices.	The viab.% of the 100% extract of the test article is the final result, and if viability is reduced to <70% of the blank, it has cytotoxic potential.	Viab.% of 100% test article extract is 21.0% It means the proposed device have potential toxicity to L-929 in the MTT method

4	ISO 10993-11: 2017 Biological evaluation of medical devices — Part 11: Tests for systemic toxicity	To evaluate the potential for medical device materials to cause adverse systemic reactions.	Within the monitoring period (72 h), if the toxicosis response of testing group is not greater than that of control group, the testing sample is regarded as acceptable.	There was no evidence of systemic toxicity from the extract.
5	ASTM D6124-06 (Reapproved 2017), Standard Test Method for Residual Powder on Medical Gloves	This standard is designed to determine the amount of residual powder (or filter-retained mass) found on medical gloves	powder residue limit of 2.0 mg	0.09-0.11 mg /glove
6	ASTM D5151-06(Reapproved 2015), Standard Test Method for Detection of Holes in Medical Gloves.	This test method covers the detection of holes in medical gloves.	Samples number: 125 gloves AQL: 2.5 (ISO 2859) Criterion ≤ 7 gloves for water leakage	no glove water leakage found
7	ASTM D6319-10(Reapproved 2015), Standard Specification For Nitrile Examination Gloves For Medical Application.	This specification covers certain requirements for nitrile rubber gloves used in conducting medical examinations and diagnostic and therapeutic procedures.	Sterility: no need Freedom from holes: pl. Refer to No. 5 in table 5 Dimensions: S: width 80 ± 10 mm Length ≥ 220 mm M: width 95 ± 10 mm Length ≥ 230 mm L: width 110 ± 10 mm Length ≥ 230 mm XL: width 120 ± 10 mm Length ≥ 230 mm Thickness: Finger ≥ 0.05 mm Palm ≥ 0.05 mm Physical properties: Before aging	N.A. Please refer to No. 5 in table 5 Lot no.: 210515 Dimensions: S: width: 82-85 mm Length 245-254 mm M: width 91-94 mm Length 249-255 mm L: width 102-105 mm Length 252-260 mm XL: width 112-115 mm Length 250-262 mm Thickness: Finger 0.11-0.12 mm Palm 0.08 mm Physical properties: Before aging

			<p>Tensile strength \geq 14MPa Ultimate Elongation \geq 500% After Accelerated Aging Tensile strength \geq 14MPa Ultimate Elongation \geq 400%</p> <p>Powder-free Residue: pl. Refer to No. 4 in table 5</p>	<p>Tensile strength 15.2-17.6 MPa Ultimate Elongation 629.928% - 788.321% After Accelerated Aging Tensile strength 14.2-18.7MPa Ultimate Elongation 601.793% - 738.384%</p> <p>Powder-free Residue: pl. Refer to No. 4 in table 5</p> <p>Lot no.:210518 Dimensions: S: width: 83-85 mm Length 252-255 mm M: width 91-96 mm Length 250-256 mm L: width 101-106 mm Length 254-261 mm XL: width 111-116 mm Length 254-258 mm Thickness: Finger 0.11mm Palm 0.08mm</p> <p>Physical properties: Before aging Tensile strength 17.1-24.4 MPa Ultimate Elongation 525.655% - 750.940% After Accelerated Aging Tensile strength 14.0-18.1MPa Ultimate Elongation 578.552% - 755.773%</p> <p>Powder-free Residue: pl. Refer to No. 4 in table 5</p> <p>Lot no.:210520 Dimensions: S: width: 82-86 mm Length 246-250 mm M: width 92-93mm</p>
--	--	--	---	--

			<p>Length 245-249 mm L: width 103-107 mm Length 252-259 mm XL: width 112-116 mm Length 254-258 mm</p> <p>Thickness: Finger 0.11-0.12 mm Palm 0.07-0.08 mm</p> <p>Physical properties: Before aging Tensile strength 16.1-19.8 MPa Ultimate Elongation 668.374% - 798.544% After Accelerated Aging Tensile strength 14.5-18.4MPa Ultimate Elongation 621.273% - 745.388%</p> <p>Powder-free Residue: pl. Refer to No. 4 in table 5</p>
8	ASTM D 6978	Chemotherapy Drugs Tested with Minimum Breakthrough Detection Time	<p>Carmustine (BCNU) 3.3 mg/ml: 23.6 Minutes (min.)</p> <p>Cisplatin 1.0 mg/ml: > 240 Minutes</p> <p>Cyclophosphamide (Cytosan) 20.0 mg/ml: > 240 Minutes</p> <p>Dacarbazine 10 mg/ml :> 240 Minutes</p> <p>Doxorubicin HCl 2.0 mg/ml: > 240 Minutes</p> <p>Etoposide 20.0 mg/ml: > 240 Minutes</p>

			Fluorouracil 50.0 mg/ml: >240 Minutes
			Methotrexate, 25 mg/ml (25,000 ppm): >240 Minutes
			Mitomycin C, 0.5 mg/ml (500 ppm): >240 Minutes
			Paclitaxel 6.0 mg/ml: >240 Minutes
			Thio Tepa 10.0 mg/ml: 37.4 Minutes (min.)
			Vincristine Sulfate, 1mg/ml (1,000 ppm): >240 Minutes

9.0 Summary of Clinical Testing

Clinical testing is not needed for this device.

10.0 Conclusion

The conclusions drawn from the nonclinical tests demonstrate that the subject device, Disposable Nitrile Powder-Free Examination Gloves (Tested for Use with Chemotherapy Drugs) is as safe, as effective, and performs as well as or better than the legally marketed predicated device under K190860.